Patents for several biologic blockbusters will expire in the next few years. The\r\narrival of biosimilars, the biologic equivalent of chemical generics, will have an impact\r\non the current biopharmaceuticals market. Five core capabilities have been identified\r\nas paramount for those companies aiming to enter the biosimilars market: research and\r\ndevelopment, manufacturing, supporting activities, marketing, and lobbying. Understanding\r\nthe importance of each of these capabilities will be key to maximising the value generated\r\nfrom the biologics patent cliff.
Loading....